tetano
Editor, Senior Moderator
Clin Microbiol Infect. 2017 Feb 12. pii: S1198-743X(17)30097-6. doi: 10.1016/j.cmi.2017.02.009. [Epub ahead of print]
[h=1]Universal influenza virus vaccines and therapeutic antibodies.[/h] Nachbagauer R[SUP]1[/SUP], Krammer F[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches which lead to sharp drops in vaccine effectiveness and long response times in case of novel pandemic viruses.
[h=4]AIMS:[/h] To provide an overview of universal influenza virus vaccines and therapeutic antibodies in pre-clinical and clinical development.
[h=4]SOURCES:[/h] PubMed and clinicaltrials.gov were used as sources for this review.
[h=4]CONTENT:[/h] Universal influenza virus vaccines that target conserved regions of the influenza virus including the hemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late pre-clinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance our preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection.
[h=4]IMPLICATIONS:[/h] Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] influenza; influenza vaccine; monoclonal antibody; pandemic influenza; seasonal influenza; therapeutics; universal influenza virus vaccine; zoonotic
PMID: 28216325 DOI: 10.1016/j.cmi.2017.02.009
[PubMed - as supplied by publisher]
[h=1]Universal influenza virus vaccines and therapeutic antibodies.[/h] Nachbagauer R[SUP]1[/SUP], Krammer F[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches which lead to sharp drops in vaccine effectiveness and long response times in case of novel pandemic viruses.
[h=4]AIMS:[/h] To provide an overview of universal influenza virus vaccines and therapeutic antibodies in pre-clinical and clinical development.
[h=4]SOURCES:[/h] PubMed and clinicaltrials.gov were used as sources for this review.
[h=4]CONTENT:[/h] Universal influenza virus vaccines that target conserved regions of the influenza virus including the hemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late pre-clinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance our preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection.
[h=4]IMPLICATIONS:[/h] Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] influenza; influenza vaccine; monoclonal antibody; pandemic influenza; seasonal influenza; therapeutics; universal influenza virus vaccine; zoonotic
PMID: 28216325 DOI: 10.1016/j.cmi.2017.02.009
[PubMed - as supplied by publisher]